PSI Advisors’s United Therapeutics UTHR Stock Holding History

PSI Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,350	Closed	-$118K	–	560
2019 Q4	$118K	Buy	+1,350	New	+$119K	0.08%	179

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PSI Advisors's UTHR Position: Q1 2020 in Review

PSI Advisors sold out of United Therapeutics (UTHR) in Q1 2020, closing a stake of 1,350 shares — an estimated $118K sold.

PSI Advisors first reported a position in UTHR in Q4 2019 and held it in 1 quarter. The position peaked at $118K in Q4 2019. 303 funds tracked by Wall St. Rank hold UTHR as of Q1 2020.

PSI Advisors reported no remaining United Therapeutics position as of Q1 2020 after selling out during the quarter.
PSI Advisors sold 1,350 United Therapeutics shares in Q1 2020, an estimated $118K.
PSI Advisors first reported a position in United Therapeutics in Q4 2019 and held it in 1 quarter.
PSI Advisors's United Therapeutics position peaked at $118K in Q4 2019.
303 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2020.

Based on PSI Advisors's 13F filing for Q1 2020, filed 15 May 2020.